866-997-4948(US-Canada Toll Free)

Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2018

Published By :

GlobalData

Published Date : Jun 2018

Category :

Pharmaceutical

No. of Pages : 490 Pages

Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2018" provides an overview of Refractory Multiple Myeloma clinical trials scenario. This report provides top line data relating to the clinical trials on Refractory Multiple Myeloma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Refractory Multiple Myeloma Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Refractory Multiple Myeloma 31
Jun 17, 2018: Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma 31
Jun 15, 2018: Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm 31
Jun 15, 2018: Update on bb2121, a Promising Therapy for Patients with Heavily Pre-treated Relapsed/Refractory Multiple Myeloma 32
Jun 11, 2018: FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS (carfilzomib) Label 32
Jun 01, 2018: Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting 33
Jun 01, 2018: Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma 34
Jun 01, 2018: Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma 34
May 25, 2018: Glenmark Pharmaceuticals Announces Poster Presentation on GBR 1342 at 2018 ASCO Annual Meeting 35
May 17, 2018: PharmaMar Announces Data Presentations on its molecule Plitidepsin at ASCO 2018 35
May 17, 2018: bluebird bio to Present New Data from LentiGlobin Transfusion-Dependent -Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association 35
May 17, 2018: Genmab Announces Abstracts to be Presented on Daratumumab at 23rd EHA Annual Congress 36
May 17, 2018: Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting 36
May 16, 2018: Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meeting 2018 37
May 16, 2018: bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting 37
May 16, 2018: Janssen to Present Data on DARZALEX at ASCO 2018 38
May 16, 2018: Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions 39
Apr 30, 2018: Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS (carfilzomib) Label 39
Apr 28, 2018: BMS Phase 2 trial of the efficacy and safety of Elotuzumab 40
Apr 28, 2018: BMS Phase 2 single arm study of safety of Elotuzumab 40
Apr 25, 2018: Genmab to Present Data on Daratumumab at 2018 ASCO Annual Meeting 40
Apr 25, 2018: Incyte to Present Data from Phase 1 Study of Ruxolitinib at the 2018 ASCO Annual Meeting 40
Apr 21, 2018: Molecular Partners presented preliminary results from the ongoing phase 2 study of MP0250 at the European Myeloma Network Meeting in Turin 41
Apr 18, 2018: Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting 41
Apr 17, 2018: Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma 41
Apr 05, 2018: Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma 42
Clinical Trial Profile Snapshots 43
Appendix 487
Abbreviations 487
Definitions 487
Research Methodology 488
Secondary Research 488
About GlobalData 489
Contact Us 489
Disclaimer 489
Source 490

List of Tables
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2018* 8
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2018* 16
Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2018* 19
Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2018* 22
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30

List of Figures
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2018* 16
Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2018* 19
Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30
GlobalData Methodology 488

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *